<SEC-DOCUMENT>0001193125-13-001565.txt : 20130103
<SEC-HEADER>0001193125-13-001565.hdr.sgml : 20130103
<ACCEPTANCE-DATETIME>20130103060559
ACCESSION NUMBER:		0001193125-13-001565
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130103
DATE AS OF CHANGE:		20130103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13504016

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d460599d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): January&nbsp;3, 2013 (January 3, 2013) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;3, 2013, ARCA biopharma, Inc. announced that
the paper &#147;Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Chronic Heart Failure&#148; was published in the journal <I>Circulation: Arrhythmia and Electrophysiology</I>
(<U>http://circep.ahajournals.org/content/early/recent</U>), a publication of the American Heart Association. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Effect On Reducing Ventricular Arrhythmias Paper Published in Circulation: Arrhythmia and Electrophysiology&#148; dated January 3,
2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: January&nbsp;3, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Effect On Reducing Ventricular Arrhythmias Paper Published in Circulation: Arrhythmia and Electrophysiology&#148; dated January 3,
2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d460599dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g460599g86s46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2100 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> EFFECT ON REDUCING </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>VENTRICULAR ARRHYTHMIAS PAPER PUBLISHED IN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CIRCULATION: ARRHYTHMIA AND
ELECTROPHYSIOLOGY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, January&nbsp;3, 2013 </I>&#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper &#147;Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with
Chronic Heart Failure&#148; was published in the journal <I>Circulation: Arrhythmia and Electrophysiology</I> [<U>http://circep.ahajournals.org/content/early/recent</U>], a publication of the American Heart Association. The lead author on the paper
is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado Anschutz Medical Campus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The paper analyzes the overall and
pharmacogenetic effects of Gencaro (bucindolol) in reducing the incidence of serious ventricular arrhythmias. The authors based their conclusions on post-hoc analyses of clinical data from a 1040 patient DNA substudy of the Phase 3 clinical trial
Beta-Blocker Evaluation of Survival Trial (BEST). The BEST Trial was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The paper shows that patients in the BEST Trial who received Gencaro experienced a 58% reduction in the incidence of ventricular tachycardia
or fibrillation (&#147;VT/VF&#148;) (p = 0.00006), adjusted for the competing risk of mortality. In addition, the authors determined that Gencaro reduced the incidence of VT/VF by 74% (p = 0.00005) in patients with the beta-1 389 arginine homozygous
genotype, believed to be present in about 50% of the U.S. population. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The study also analyzed the effect of two other genotypes on
Gencaro&#146;s effect on VT/VF. Based on a statistically significant test for interaction (p = 0.03), the three genotypes provide a potential method for identifying VT/VF patients for therapy. The first group is the approximately 50% of patients
with the beta-1 389 arginine homozygous genotype, who had an enhanced response (event rate reduction by 74%); the next group is the approximately 40% of patients with a second genotype (beta-1 389 glycine carriers + alpha-2C 322-325 wild type
homozygous) who had an intermediate response (event rate reduction by 49%) to Gencaro; and the remaining group is the approximately 10% of patients with a third genotype (beta-1 389 glycine carriers + alpha-2C 322-325 Deletion carriers), that had no
response. This pharmacogenetic approach therefore defines a target population for Gencaro that has a potentially enhanced response, as well as a small subpopulation that may not benefit from therapy; the genetic identification of such
&#147;outliers&#148; in drug response is a major goal of pharmacogenetics. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stuart Connolly, MD of McMaster University, an electrophysiologist-cardiologist, commented: &#147;I believe
that beta-blockers have only modest effects on prevention of serious ventricular arrhythmias, but in the Aleong et al study, patients with the higher activity beta-1 receptor genetic variant (389 arginine homozygous) had a significant (by 74%, p =
0.00005) and genotype specific reduction in the risk of ventricular tachycardia or fibrillation. This suggests that bucindolol may have clinically important anti-ventricular arrhythmic effects in the roughly 50% of patients who have the beta-1 389
arginine homozygous genotype, and I believe that further study of bucindolol in additional clinical trials is warranted.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Will Sauer,
MD, from the University of Colorado Anschutz Medical Campus, an electrophysiologist-cardiologist and a co-author on the paper, said: &#147;While the use of beta-blockers as a class of drugs for prevention of ventricular arrhythmias is not well
studied, it is commonly thought that any beta-blocker is potentially helpful for any at-risk patient. However, the research presented in our Circulation AEP paper shows that patients with the beta-1 389 arginine homozygous adrenergic receptor
polymorphism experienced a 74% reduction in VT/VF events with the beta-blocker/sympatholytic agent bucindolol. I believe that these findings have important implications for the personalized treatment of patients at risk for arrhythmias. In the
future, physicians may look at a patient&#146;s genotype prior to the initiation of a particular beta-blocker or other anti-arrhythmic. I believe that this is particularly important in the prevention of lethal arrhythmias like VT or VF, where the
current practice of assuming that any beta-blocker may work could be harmful; for example, if the prescribed beta blocker is not efficacious or if a more efficacious beta-blocker for that patient is available.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Bristow, MD, PhD, Cardiologist/clinical pharmacologist and senior author on the paper, CEO of ARCA, also commented: &#147;This 74% reduction in
VT-VF in the beta-1 389 Arg/Arg subpopulation suggests that Gencaro warrants further study, such as in heart failure/reduced left ventricular ejection fraction patients at risk for ventricular arrhythmias, who have implanted
cardioverter-defibrillators that are having appropriate firing. This could constitute another indication for Gencaro beyond those of atrial fibrillation prevention and heart failure.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ventricular tachycardia and ventricular fibrillation are serious, potentially life-threatening arrhythmias, and the most common cause of sudden cardiac arrest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has been granted patents in the U.S., Europe, and other jurisdictions for methods of identifying and treating patients with the beta-1 389 arginine
homozygous genotype. The Company plans to conduct a Phase 3 clinical trial to evaluate Gencaro as a potential treatment for the prevention of AF in patients with this genotype, including measuring VT/VF data as a secondary endpoint, subject to
receiving the necessary funding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory
Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain
&#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to
predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, Gencaro&#146;s potential to treat ventricular tachycardia or ventricular fibrillation, and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in
the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business
objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and
the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the
Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g460599g86s46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g460599g86s46.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#,`P$1``(1`0,1`?_$`+4```$%``,!`0``````
M```````&!P@)"@($!0$#`0$!``$%`0$``````````````0(%!@<("00*$``!
M!`$#`P,#`@4"!`<````#`0($!08`$0<A$@@Q$PE!(A11%6%Q,B,6D4*!4A<*
MH7(DI-08&1$``0,"!0(#!00$"`\``````0`1`@,$(3$2!09!!U%A$W&!D2((
MH;$R%%*RTA7!T4)B@F07"?&2(S-SL],TI#5E=18W&/_:``P#`0`"$0,1`#\`
MW\:(FDSGFK!\"E)`M)KYE@FWNP:WV9!X^_I^1W%&P;MO]JKW?PUU=[T?5_V8
M[&[B-EY5>SN-\PUV]J(UJM)\O5&H"!ZZ21)F+8A;QV#@V_<AI?F+2`A;])3<
M"7LP+^U(0?E+@!5V'7Y$_P#\L2*J?Z_F;:X>VW^\?[';Q/1MEEO]8_S;:#?'
MU66OS[3\AI_CJVP_I2_97;_^S&$;;_MN0_R_%B?_`#-;K_\`NGMCHU_NOD#,
M_P#N]/\`VR^?^S'>W;UK7_&E^RNH3REP`2[$K\A8OK]T2*B;?KNLS;6T]Q_O
M(.QNTS-/<K+?Z,A^E:Q`QRQ]5E]$.T_(JF,*ML?Z4OV4XV"<O89R"]\>FG*"
M>WN5*Z?[0)A6-_J>%C2/:5$^J-55VZ[;:YT[*?55V@[[RE:<.OC3WF+M:W.F
ME7E$9RA#4=8'722>K,MM\@X9OG'`*E[3$K<_RX.8CR)8-[TZ&NR"VFC1$:(N
MN&9$D%DQX\J.<\(C!3`A.(I8A2#:88Y(V.<\!"!>CVH]$56JBIT71%V-$1HB
M-$1HB-$1HB-$75F385>!TJ?+BP8S%1'R)D@48#%<NS4<8SV#:KE]-UZZ(DY%
MS_!)QEC0LUQ*9(:JHZ/%R2FD&:K5V<BB%->]%:OKTZ:(E4Q["L:0;V$8Y-VO
M8Y'L<GZM<U514T1<]$1HBZPYL,TJ3"%+C%FPVA?+B#.)\J*R2CG1WR8[7J4#
M9#6.5BN1$>B+MOMHB[.B(T1&B).9A;%HL6R"Y`U'&K*F;,$U?17@`][?_%-;
M&[F\BNN(=O-[Y391$KO;]KN;B`.1E2I2F![R%J6S6D+_`'6WLIX0JUH1/L)`
M500#R\DLI5K->Z0:=()+D%*Y7$>\[U?VJ[U5!M5&_P`D37YA.&\4WSO#RRXY
M3O=2=:M?74JU:<Y/*<JAU:3)L8Q!$!Y1"[CUC1VFUC:40(PIQ$8@9`#!_P"%
M._C>)FEG%$8!HB&8Y0N=NC2*UJJT;?HKB*G:G7U77I?VU['VMM3I6%&WC2E*
M'REAB6=AAB3EGFM@[KOD:<35,M0B<?+_``9I:_X+*?`BF9&59![`]>X?8J=I
M!J)K$<OT_K557Z(FN=!V>%3;:=2G0!KSKRI-YAF?X_8MO_\`D,(W$H2E_DQ3
M$O=BD/DN,I&+*CH%2?BO<$SD3[&F&JL/L]45%:I45&_JG77`W=#LIM][1N+&
MK0A4A2.F4M.4HX2Q\-0+'J.BW%M.]2G&-0EC,./8<O>V?FFLARYF+Y!5VD(C
M@DAV$4X3#5['HC)`^YBN:YJJCVJJ*GHOUUYS7O']\[,=RMLY-LM2I1_+;C0J
M4YPD1*,15CJ@2&)$HN&)8NQ6^*D*&[[95M:P$HSI2!!8C$'[BK@J.Q2WIZRS
M:U6I.A1Y/:Y-E12#17(J?3[M]?J$XKO4.1<;L=]@"(W=K3JL<#\T02_O736^
MM_REY5ML_3F1\"O5UKZ^1)+/<SI>.\+RC.<BEB@TN+4L^ZL))W=HV!A`<1K%
M7_F.5&L:GU<Y$T149?'+Y86^7^3_`"C3YO.L`_\`6N5.RFC@6?NL;62VG-.J
MZX3"OV&UM,448*;+W-8WK]=%<%?UHHD;G^"4')6*V6'Y+^Y)46C&-D/J+:PI
M+$;AN[QEC658>/+`1CDWZ.V7ZHNB+.%\A&"6GB)GV.QN,.5^6V4F98Y8VI*V
MYS[(;0E<^$;V"QHTDDP:?C%WW:G9WL3IW+ZZ9I@`Y*LJX1\`>/;OB'$KK-^2
M.;K[+,MQ>LNK*XC<JY1!!`EVT9DY%HH:22)$8$9VMV,X^[FJO1%V0B@UR[RA
MSW\<7.E/C\'DG)>2>([J..W@T.:3W7!Y=2PRBE0Y5G*8Z6&W`WO5AF.:SZJQ
M4Z:8GVJX#V*_W`LQK.0<,QC-J;O2LRBF@W,-I$V(,<P+2*)^W^X3U5J_KMHH
MJ^O-OY`JCQ\.WC'C:&'*^9[50`'$(%\FJQMLQ$0!)PPO&298E[T4<='-VW1S
ME5.FF:>'FD1P-X9<@<S0H_+/FGG.:Y9?W:"F4O&L3))M)C=13G[3LCW]?3?@
MBD22HC>T8_:<!OVJ]R]=$4C<I^//Q8OZ8E=4<?DPBQ;$=%@9'B.09#`NH#>X
MI6J,TBTEA/\`WS*YWN,>YWIW)HBA1XU\/\H>*?FI%P7-,RR'*N/LWQ:Y3"+:
MPOKNSBS7A8<@XTJOG3CQ(=I%5B=ZM:JO1%<G;Z:BR`^Y79ZJQ7GVUI`HZNPN
M;22*'6U4*383Y9G(T4>)$"\YS$<JHB-&-BJNB+/!XH^9UA=>?65Y#DMC:Q,0
MYXFS,8IX%JYXHE1"CD=)PHZB([L:U/V]8@7MZ*DI?7?5Z>2>3K1?J(C1$:(D
M%RD_V^.<V?\`\N-VJ_\`M":XG[[QU=E^51\=@OA_P]1:_P`6QY'8C^LT_P!8
M*J?!7@(V(AW*T3VB[G,Z*C7-;]_:OJJ:\9/IIXWMUKL=GZ\<)4XF4AGB!\5V
MEY+*H)ST?B!*EB.RJL0QF-:(85PXDZ.RE8]%!)BSV*TKT,K>URQNQ%Z>F^O2
M6>\[1P+C5M?1,;NM6N(QMHGY9PF/F)EE\C`X+B`VUUO&Y3MB#1`@?4.8,3AA
MYIR,/L[N]'^>B0&-8\LMD=@&()ABB497M56]_=VN_P!=<L\2O]WWBW%_6]$%
MS4TB($09!B1@[^:VUNUK:6<_0&O+2Y.)`."36;5-62D:=)`ZZ$TI&F&U%-/G
MV:*KB*9?N[1C:N[4]$3KZZVISW9-KN-DE,SC;V>HZP!JJ5*O74?T1F!EUS6I
M;)=W,+W0QJ56P)PC&'EY^)]RACE*A;*'[?<C4DL1JKLBKL5JH[9/3TUY9=^^
M-;?6&NF,(582BX#N*D5SCL4ZAIG5GI+_``*MBP-=\-QI5^M1$7_4::]K>U.'
M;;9!_P!-H_J!=4M]_P"<W/\`II?>E;KD!:2JO_D+S&RSJ\X,\-L2F*"Y\@,V
MAGS:2%5(ZJXVQ<P[.W9.`S=S8MT02#:]4V1P=,U6.:JO^0FDE>)/FMQ_RE@L
M!M1CLJKPNRH8H_<#`!)P^NKZ4U:US%12,+&K/=(B[JO<N^C.F6/1:6N-LVK.
M2,!P_/:8B%K,MQ^LO(;T5%3VYT9A5;NBKU8]5;_PT42VT19J_G/LG0>0>(VH
MY$1^!Y*[955.J3VI]/71G5/X<,2K]N#ID87!O%4T\D`HS>.,0,624K&`8S]A
M@JY[S.<@VL3?U5=M09*+/G\F^9$\FO)K!.'>%(Z9M:XW6+!L9=(Y9T<-I8&5
MCA//&4@$!'"7N<[?9%1=]/-4A\%?9@M._@'QRI:RTD-ER>.>.^^<;9$86=75
MKY!6(B)M[:2OLW^J)OID%2Q*S?\`@W%E>5_GO/S7--K`%1976;6`'.4[%-&E
MF!2,_NJ[^R!T5/M]-OX:$,G4EL%J\:UK&M8QJ-:U$:UK4V1K439$1$]$1-58
MKEHB35OB&.7MO17UM51IEOC)S2:.<5J^_7&D"<$SP.14V]P3E1?U3495RE+J
MJ*NKY'.5[/&.+\9X=Q(Z,S?R!RB%Q]7*S=Y(=+,*)M[.()FY$$Z(11H[;;=5
MU,%E$*IGY2N$1^-G(/C]RQQ_$?`QZ/CV)XPB-:T,:#D7&DB'/HV[BV[I%O"0
MQ#*OJHEU0%CB2ZT1<%<G5W,O$/'_`"76D80.68W`L3H-S505@@_Q[(6S?Z49
M."3M1>O;MHJ<"G9T41HB;OEMW;QEG;DZ*W%[==_Y1":XK[XA^SG)QX[%>_ZB
M:W#Q,/R:P']:I_K!5'\;7Y&O@M`4`%:P2.>;L]IJHUJ]SU7=41$^FRZ\<OIN
MY!*GMMG0H5*<:@C$?,S18`8O_$5VMY581/J2F#(8Y?P*3&=AL<EP6,:BFNR*
MUQJ<RQL8T&.P<<<$K/:5(K^YCI,EKW_T=J.5OINO37<CO-9\AY!P>QWSBE26
MX[ILUSZUQ2HQP]"<=)]/(SF"7TL"1D"<%QGQZI:;=O=2E?P_+VMS3T0,BY,@
M7Q_1##/)\TE,/Y8M8`4K01K1LO9!)"2!,_*55Z*GL>S[C=_U5-MNJZTG@/?@
M_DJ=C3C<_O`Q`]+TJHJ/DV@PU`OG@WN6H;QQ*A5J&YG*GZ&>K5'3\79/9/LI
ME7AX(UM8_M%_;&)=I'G@82"6*4:11C9-:XJ-,P8T5[6M79VZ+Z;Z[`;AN=U8
M\/`W6N+3>;N1N-%6(,-!&D1$P2TF`)`!8N"MET+:C<;L9VM/UK&B!3>):0(+
MDZ<,'.!]ZA/FU\0EB-"$&0B21MW"K48O<9J*YNR)NCO]=OIKS,[Z\CC6J2HU
M9P-4U8`,S%YQR;[%SAQZQC"@91!$=)S]BN#X_5783B[E]5IH2]/3J)->T?:K
M_P!;[)_VZC^H%U)Y``-[N@,O6E]Z5A2B`(ASD&$(1O*8Q7M&(0AM5Y"$(]48
MP;&(JJJJB(B;KK?ZT=9X^.A^4?E9Y:<W>7?CI:X3"H,(M++@7!['/:MUI$96
MT2C6[2E"PXQ-E)+*CWG:O5ID34?#JLLBQR9-_P#)%P-YRYCPD3D;G&VXQR:H
MXI*6Z$F%T!H-Y%B26^U.)[C#R%)%:+=7)MZ:#WH69@I;_")Y#$Y7\<+OC>WL
M5EWO$-Z.!&209KI#L=NFGDUX@L[E>L6N?'4>^R(WW$354.(=74Z*++'_`-P+
M=/J>3>%58YJ*O'V3E1'*FSE'9C7JBJFZ=-1L52^GWJ1O/O@YE+/""@Y6X(Y0
MY7AYG1<88WE]AAC<IFRZ;)*DE)&G7-5!@,:U021M,KP;+LUC')U54T]JKDAA
M@FT^$+R4XULKC)N%<NH\<K>5I#Y%QBN83`"%D>1Q%57V5!,F3'.D%GQ"HX@V
MM5KU:JL[55$U5')#K0'SK12,FX:Y.H8C7/DV6%9``#&.5KWD;7F*UC7(BKW.
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MU0UEA<B/D^,Q99D_+6DMD6//AQ`N^](];)C,>]/]KI&KU4S'F%H"T41HB;[E
M>.>5QKG,:*-QI!\8MQA$U%5Q".B$1K&HG555=<:=Y;:O>]I^1VEM"4[BILUW
M&,8AS*1HS``'B3DM?XK4ITN26-2J6IQN:9)\!J"H-K;<U81K%56N&Y&%:J?<
MP@U]LHU;Z(YKF;>FZ:_.EPC?[GBM>G"K&0IP82CBXD,#[P00?,+O7>V4;J)E
M%B#E[#B#]JD[Q]S"R$2NCG<L:KK2I9%`)_MK-FQT]P#I1$7O+WF:B(W?M:B]
M$UZ$]K>]UO2C;TJDQ3VVW/K2C&3&I4CC$R+N7D`&?2.@"XJY!Q"585*D/FNJ
M@T.0^F)STC(8?%/3&\@00X=??^S#?<.R&?(E';$BME+6N&./^.Z2T2'<WV)#
M^S[MNY$WUS;1[Y[/:VU'D8H6G[YE?U)3J"E2%7TV$=/J"(F?EE)L<ULZ?!:M
M6K.PU5!9BWB(QU'3K=WTNV8#^28O.N6TE!L:@9WS:=TTL^H0Q7$D5?Y+E(QH
MBJJ]C7!<UIAI]G>BN:B.55UP+W([U6OY.YL/4-7:Y5C4H"1>5+47`!/C$B,X
MY.Y`!Q6]]BXI*G4IW)B(78@(U&#1FW4CKCC$YLP+A1Z?;'M[.")G<KBV$5@6
M;[[O)(&QFVW55<Y>N^NAG(-ZNN6;]0$8G1*XIP@/$RJ1`?WG!<ETK2%G;3E)
MA$4Y$^0`)5_N$Q#U^(8W$E(C9$>F@,,B>C7(!BJG7TV1>NOT?=O=NN=IX-M.
MVW@`N:-A1C(`NQT!=#=[K4[C=[FM2_S<JTB/BJLOEF\]L$\8O&_,<8H,EKK+
MEODNFM,3QJDK)\:1-K8,\#X=[;V`Q.>:*$5:\P1.3M>DA[514[=;P=\EIC-F
MG<^*O$,-P#PJX>QW&,IJ\GF6E3(R[(9L.5&++/?WY&2K)\\87>Y^4'^V-[GI
MW+VINN@*$,II<M5F*Y#Q[EN+9?855?39)06E5*);2@18OMR8I!JY[CO8CFC5
M454_AH4&:Q8_'5Y5XSX-^=>;X7EN2CD\97.4W?'5YDD5PE@.&*=W5%RXC4]A
M80I*L[GMV^UJ[+H?%!\I,5MFH>0<&RBF9D./9;C]Q2$`*4VT@6L.1#0!F(\1
M7F856C:]B[IW;:.$8C!9$?\`N'.5<-R;FCB:DP_)JC()]!QU?QKL=3*CV#:^
M393F'@@.0#R,80P?NVWW30'%20P8K2]X9<Q<5\L>-'"1\0S#'<A#+XSQ>KD5
MPK"&2:DJ#3!K+.#*KE*IV/9)BE8YCF]6I^FJKCFLM?RN>,>9^!WDUC_D9P\4
M]/@F:9(F4XU/K6*)V'YQ&D)/F5KWC3^W'FR&J8:N7MW>C43;IJ/XJ$'\86DC
MP?\`D(X3\O>(\;O@Y70T6?-KHE=F6%6]G$!8Q;H4=@9A!`D/:IX<XS7.'ZKL
MNR[[:/XK)CF,E0I\DWA]S9X6^2<7SAX"AMO>-)F9P\L4-)#D/D8;='4!;*JO
M!1%^^BO)#".$42,9V/1B_<U54XRZ*?SA^(*_+P:^1'A+S2XZB7E%;Q<4SZK9
M%K\QX_R"PB1[JLMO8;[I8K'.#^;`E$:YPGL;T:J(OZZ.C/B%.VWR&AH(1;*[
MN:RI@`$XQIEA-CQ8XQ,;W.(XAB-;VHU-]50!\EGM\S_D)Q3R-\C>#_"?QPRR
M]DK:<GTI^2N0,2MY4"O-"B''V8S7SJLP)1=Y'W2'H3L5J=NVL?N608%NO\2L
M/^0_S(P;Q(\7>0[8>3U,SD9^+2,9PS'&6(CV\V[F1?V[\@H&%=)&V&%SR.>N
MSN]$^JZ/A@C=3DFA^&/%,/Q/Q#QFTAY729%FW),^=F>6GC3`DM5FSS$*"+8C
M<5TI\F$!Z#<YVZKVZH0NP\%:WE"4Y:"WA7TN'#JK.MGUDPL\X@1ECSHAHYV$
M>9[&=J@>[=-_3?56(6$G@CR`H_`#Y*;^:V\9=<;XWR-D>'Y)9TCF2(\S#,DD
M#G%?"</<!Q0%EC;O]$"NRHO74Z*X"1CT6YG`.3<!Y2H*S)^/\LI,JI+>#'L8
M,VHGQY;2190FF"1S!/<02JQW5'(BIHZ,1FEWJJ+@0;"L>(C4>,C7,>UR;HYK
MD5'-5%]45%UA4IPJP-*H`:<@00<B#@0K&1C(2CA(%5D\Z>$=M874S).)Y$=@
MK$Y)4O'IINQ@91G.(<D0SMD:)[EW1B?7?7F%WP^A2YW'?*W(^U4Z<:5U4-2I
M:U9,(SD3*9IR\"2XCXDKLCPKO1;4;.&W\I$C.G$1C5B'<#`"0\6ZJ-@O$7R#
MCO51T<9-E5%[971=NG\EUU]H?1WWWLB1;6M.+'I,M@N0I]U^!U!\U:7P7=7Q
M7\C%9[:TT?L155&_E=$5=MU3^*[:U@_2U]19I>B:,/2=VU=5\W]IG;U]7JE_
M8ND3Q$\@3O\`OHXRHY43[I73KLB_R3?6CU_HZ[\7L@+JVA+'K,L"Z^F'=?@=
M.+1K2^"E5P+X3RZ"XAY3RE+%(E5AP2J^A@%1\9907M*Q\PS=VE$Q[47M^JIK
MLOV)^A@;!OE#E?=&I"K<6E6-2C:TB\/4@7C*I+^5$''3U*XSYQWFIWMG/:^,
MQE&G4B8RJR&.DX$1'0GQ5CI`L(%X%W:,@G!5&+V*UCF*Q>Q4ZM5&KT5/37I4
M`(@1CA$!=>')+G-5?7GPZ^#&57-KD.6X%E65W=S93;2=9Y'GV16LM9$XSCF&
M$DF0[V(K'N7L&W9K$Z)HS*F3XEG3[>-W@1X[^*&3VV4\*U>6T!;FL)52*6=F
MMW<XP".8T<Y2P*&<<D&'+>^*S<C$1VR;?71E'P9+GR4\3N)O*ZAI\;Y93+WU
M-),+,C`Q/+[C$GR'F8@RBGEJ"B),C/8FRC>O;H0Z`LH=_P#XJ_'HO5W#TUSO
MJ1V5W;B.7ZO<13JYSW+U557=5U4?V)T\%^,?Q<XWP3/N-L-B<E4^)<CCB"OZ
M\/)N4.?''">1X64<A\IQJ9JJ5>Y`JG<FR+Z:C*ZB$U(_A4^/M!L27Q9>6LA$
M_N3[C-\@LK"2[ZEE3),AY3%=]55=51_8G#XF^*WQ!X-Y+Q3E;BW&LUQ+)L/G
MMLJR)7\@Y&W')4EL>5&3]WQ]TE:^S%[<Q^[2-V[ME]4349']BE+Y$^-W$/E/
MQS-XKYIQE,FQ"=*C35C#E&KYT6;#>A(\N!81E;)B'&]$7N8J+TU4!90>A_#!
MX$U1(DFCX[RG'K"":,>+:4.?Y)5V0BQ7L(-R2XTEKU[G#3OW_J3UT9`6\%9G
M&Q.A#BT7#)$$=MCT6HCT:P;I&VK9E?'C,B-'8+,:3\QY`L^]ST57+NJ]=1NB
M$N75;?(WP^>%V<9F3D3'<6ROA_,W)]EKQ!EMEA$4;W$:0IDJ:_\`]![Q51=W
M(U%3?I^FC*B7BO*LOB(X.RB,ZKSWF;RCSK'R#41Z&]YJR!U>=BHB(PJ#:CU'
MLFRHBINFHWFJ9NGLX$^-/PV\;,@K,MXOXD@0\KINQU5DEY.F7]U`*Q$1IX\Z
MP(0K#]-^[UWU66+^";_-OB0\+.2<LR+-<_P[+\PO\FMI5Q/DW^?Y'8!CR9;U
M>85;&+)4-?#[E^T0T1K=&94R?P3@<#?&]XN^-6>Q>1.'Z#+<9N(<0\,5=_F]
M]-QIPY**A2%H))WP"2%1>CU;NFC)JP;!/_Y!>/7'_DQ@3N-^2B92/&B64>T*
MF)9/9XG9%/&#(`T)+.I(*2Z(04IZ/%OVOZ;^FJH"R@JGPJ_'KLWOX@GF>C6H
MXQ\MO#'*Y$1%*8KSJ\I2*F[G*NZJN^B/Y!2-\;/`GQX\3<AN\BX5J\NH2W\9
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MW756*]&++BSHXI<*2"7%.Q"`DQBC.`PW=4>(HG.8]J_JBKHBCPOE)Q8SG&UX
M'D6\>%D]/4Q;*;83ID6)4))F/&,5,(YGM]RT[B)N/=%315L'3\W<H,6DM9I9
MBPH\>MF27SAN9O&$*,0BR6.<CF;C:G<BKNFH<D&:K*\&\YFWEYS#RKR-R28U
M5<9E)P;!&Y7D,<`)];63'E;.K(IBQXJH9Z(Q'C&F_5-UV73,JG)@K2FN:YJ.
M:J.:Y$<US516N:J;HJ*G145-58I/6N7XK1'C1;G(Z2LES)0X42+-LX<>5)EE
M3<<<,<AFF(5Z>C4:J]?XZ(NW<7]'C\)+*]N*VFKU>,:3+.;'@QE(94:(:&DD
M&Q7D5>B(NZZ(N,3(L?GV)ZB#>5$RUC1PRY%;%L8DB<&+(15!(+%$9YF!*WJU
MRMV5%1?14W(OLO(:"!.%63KJJAV)Q$.&#)L(@)9`":KRF;'*5I5$-K557;=J
M?KHB\;_J'@7[?*MO\SQ=:R%*2%+L$O:U8D>6KD8D8LA)/MM,KEV1N^ZZ*L4K
M`'!*"*1&,*1',QI`G`1A0E&]-VD&0:N8]CDZHJ*J+HHO'N\HQO&HY)60WU12
MQPM8\A;.PBPFM80C`C<J'*Q51Y7HU-DZN5$T1>R$PI`1'`1I0G&PP2L5',((
MC4>,C')T<U['(J+]471%^FB(T1&B(T1&B(T1&B(T1<7O:-CR/79HVN>Y?T:U
M%<J_\$31%03-KL:\B.=_(+REYAO)=5P!Q$2;@%1C\*P)$-R"^A<2&.H"811D
M`*RD!1AF!5'&*[M7=JKJ/TZK(A3M\",`F<1>*5S(O$+A4#)\DY!Y,JXY&L>?
M#\7O01R5(W#DHHWEK(->A4:]-G+ZIUU74;%DPWQOX[BV<\E\U>1,/(IMS*RF
M8M#C#;N:R3D]SCM/+)52<_NVB*](ZY980R$%&3^S$8[VQ(@VM33JR=$D+GD7
M'>9^6/*OF'EZ("TXQ\5Z^?@6#X7<"$6K-F%G73!R+4L,Z+&FS3J/N`YR*0:M
M7M^NHLF4AO".7>X3X.R\JY,L[&JJ5A9GEM;)C'-$L*7#Y'ORX#()7JQT4T9J
M.]I6JB-<J;:?<H3DJQ&\<8S9^$G,W,V6T8LDY5Y^Y(@T?#$_)2_Y%F0I;L@B
MCKGU-[:K(LU/:PE<CWC)W.5WW:N"JMS\F\TM^&?!F<.R(8F=6''F,<=5`5>1
M3S<WR"KBU0(;B$7W.]2M+W*O5>Q=%B'!P5:')_B-2\:>*_$.`S@"SKR*Y!S+
M&JS''&FFD_X=&L+(%A:4=+&1[VU[(K3*Z8]J-4A$>CMVZCJ@$%6B<\\VW7$%
M'Q9PIAIHIN6.0H%=CM;;VAVN@8S!@P@Q[G*+%"*I#?B#&]0M7HKD15]-"4;%
M5\\<4'%?-7F[C5;"L17>/\#Q2BN\^R`XIMWR[RDKW3),ML\SB22!ISF1@!(Y
M4''8Q$1$VT+NR99=$Y'RIX^?D;*.`.$<3)*M^2N4;Z1`Q^BG/]W&L?QRO>(U
MYE[:M%49[F$=HV*=[5<V`IQ(NSU:M6*G5P;X=\0\$64'.*2%83.3&X<#&,ES
MFPNK67(OF#$%9DV5#DRGPD(KH[&"=[:/'&$,2+VL1-$\E3MG=?C')7D?S9S-
M=Y/DUCQ#P!6V,/+,GER/QYN?Y+)E/2#Q_7DB/2/#IH3WMC%`)44P6J1[5<JK
MJ/TZK/JZ8:+P[#@\;TH<HCQ*+)/*#-@3N/\`#I!%BXQQOA23D)(RVR@KV`2?
M*B-0<8K6[(KG;K]VGL09?-FK[>4>6\>\2/'O!X]&-F56YX^.\?<<5YI+`@O;
M^8`4.OD3)"O;VUD=RH4ZL57^VGV]5T?!8MBQ58?,47`.4.?>)?'.ZRJ'G><T
M684')ODCSQ<F$>)":*0`=;QGB(3N>&@QFTO9T>(ZOB^V(17!W8C]],$;KU5_
M\>.&)'!%C"8&/&"*.`(VHT8@A8T8A,:G1K!L:B(GT1-51?MHB-$1HB-$1HB-
M$1HB-$7`HVE&03TW85CQO3TW:]JM<F_\471%"K#/`7@7#,CDW@1Y?>UI<EFY
M=%PG(LA6PPBOR&?*?,/9@HFPP(62DI_>WW2/:U?]JZ+(R*D_R)Q]0\F8!DW&
M]\Z=$QW*Z6106/[+)_;9P:^2UK'L@R1L<D5R,;VILU4[>FVVBQ2"X!\<N+_&
MO#A87QE528T+='2[.UE)87=DK%5`-FS_`&@(\,4:HP3&L:UK&ION[=RD\NB:
MK+/!/@K,LROLMMH^4#BY7D%9E65X;`O?P\.R7(*=IV0;"XJ1Q5?)<ULE_<WW
M41^_7499:BRZ'G#QIRCGGCE*XCX(IHHYN26>/XY8A#(!6Q*K!VR&,N6!:[L9
MV?AL1B-;UV^BZ9>Q0>*.)?!KBCCX'&LJQ/EF4'XTKHW^)4.37K;+&L7M>T93
MSZRL9#CL_-%(1?;*]SE8B=-`%24_?+G!^"<W`P^'GP+.;7X1E];G%370YZPX
M4F^J!R!UQ;4*")^=&B_DO<T:JU.Y=]]50%DWO&/B/Q5Q;GEWR17&RO)<IM[6
MVN(LC,KY]]%QR9=E,6P?C<0L<3*M3-.X>Z*Y6CZ)MZZC(Z_#G#P\X?\`(',L
M4SG/F9,EWB`U!7K17Q*@$B,I/<=%G,&`CS`([HY&N:KF]-]$!76X6\+.">!L
MQR3.,#HK$=WD<PDUR6MDMC"J"E8P95I8SPL_$>4;$:]RN>YR?IJH_@G+L.!N
M/+;FNCY^M(,ZPY"QG%IV(X[(E3E)54M;9%82>>NK5$B`L936JQYN]=QN5-NN
M^BB=BTKPVU;/JY#SCCV,.1".2,3V9#!21."1P"HCE&5&/7M=LNRZ$.&11"-X
M'\`FXM#P^L#)V8>F</Y"LT%D+F6N0Y(\RF4V06*1%=9Q=U[?:<UJ=O3^.HRN
MHKV\R\,.$,\Y1P/E?(JNWDW''-1#I,;I!V?LXN*OKV]L0,FH:!4.T2HCMN]N
M[DW71D?XI2^0GB_QAY+8_B^.<ACNX\+#;P>08^;&K/\`9I<&P&%(Z.&5H#M1
MB!;LB=O3Z:J/XINL(\!O''C_`)7_`.L%#C5DN1CK8%?%KI]L2;C\<E<U$!:?
MMQA*21;=[4?[I2O3O1'=O<B*A130T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1
A&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
